KOLMAR-HOLDINGS
Kolmar Korea (KRX: 161890) joins forces with Amazon, the world's leading e-commerce platform, to support the successful global market entry of K-beauty brands.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240708461379/en/
Sang-hyun Yoon, Vice President of Kolmar Group, delivers welcoming remark at the Amazon K-Beauty Conference Seller Day (Image: Kolmar Korea)
Kolmar Korea announced that it has jointly hosted the 'Amazon K-Beauty Conference Seller Day' with Amazon on June 27 at the InterContinental Hotel in Seoul.
The event was attended by about 1,500 individuals, including officials from Korean beauty brands as well as those from the distribution and manufacturing sectors, both online and offline. Key attendees included Sang-hyun Yoon, Vice President of Kolmar Group; Hyun-gyu Choi, CEO of Kolmar Korea; Jim Yang, Executive Vice President of Amazon Global Selling Asia Pacific (APAC); and Yuki Suita, Head of Consumer Beauty Business at Amazon Japan.
In his welcome speech, Sang-hyun Yoon explained the event's purpose. He said, “This event, organized by Kolmar and Amazon, is more than just a business partnership. It aims to spread the innovation and value of K-beauty globally. We hope this event will be a cornerstone in exploring global opportunities for K-beauty and sharing detailed strategies for implementation.”
The event came as K-beauty is gaining a great popularity on Amazon, and both companies want to actively support Korean beauty companies’ entry into the global market.
K-beauty is so popular that sales of K-beauty products on Amazon's global store rose more than 75% last year. Kolmar Korea is leading this trend by securing new contracts with 253 customers, predominantly indie brands, marking a 48.7% increase from the previous year. The two companies plan to keep identifying standout brands that drive global market trends with compelling concepts and innovative technologies.
At the event, Kolmar Korea established a large-scale booth showcasing skin care, makeup, sun care, and cosmetic packages. They also provided customized consultations for the global cosmetics business. Moreover, Sang-Keun Han, Vice Director of Kolmar Korea R&D Complex, delivered a lecture titled ‘Deeply Grounded Confidence: The Competitiveness of Korean Cosmetics.’
A representative from Kolmar Korea said, “This event is significant as it marks the inaugural collaboration between Kolmar Korea, a global cosmetics ODM company that has driven the growth of K-beauty, and Amazon, the world’s largest e-commerce company. Kolmar and Amazon will pursue shared growth by offering the optimal pathway to support our customers’ successful entry into global markets.”
Event highlights video: https://www.youtube.com/watch?v=sbqXL8fBgpM
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240708461379/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom